{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:07:07Z","timestamp":1793329627886,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"\n Importance<\/jats:title>\n Correct diagnosis of ovarian cancer results in better prognosis. Adnexal lesions can be stratified into the Ovarian-Adnexal Reporting and Data System (O-RADS) risk of malignancy categories with either the O-RADS lexicon, proposed by the American College of Radiology, or the International Ovarian Tumor Analysis (IOTA) 2-step strategy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the diagnostic performance of the O-RADS lexicon and the IOTA 2-step strategy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Retrospective external diagnostic validation study based on interim data of IOTA5, a prospective international multicenter cohort study, in 36 oncology referral centers or other types of centers. A total of 8519 consecutive adult patients presenting with an adnexal mass between January 1, 2012, and March 1, 2015, and treated either with surgery or conservatively were included in this diagnostic study. Twenty-five patients were excluded for withdrawal of consent, 2777 were excluded from 19 centers that did not meet predefined data quality criteria, and 812 were excluded because they were already in follow-up at recruitment. The analysis included 4905 patients with a newly detected adnexal mass in 17 centers that met predefined data quality criteria. Data were analyzed from January 31 to March 1, 2022.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Stratification into O-RADS categories (malignancy risk &amp;lt;1%, 1% to &amp;lt;10%, 10% to &amp;lt;50%, and \u226550%). For the IOTA 2-step strategy, the stratification is based on the individual risk of malignancy calculated with the IOTA 2-step strategy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Observed prevalence of malignancy in each O-RADS risk category, as well as sensitivity and specificity. The reference standard was the status of the tumor at inclusion, determined by histology or clinical and ultrasonographic follow-up for 1 year. Multiple imputation was used for uncertain outcomes owing to inconclusive follow-up information.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Median age of the 4905 patients was 48 years (IQR, 36-62 years). Data on race and ethnicity were not collected. A total of 3441 tumors (70%) were benign, 978 (20%) were malignant, and 486 (10%) had uncertain classification. Using the O-RADS lexicon resulted in 1.1% (24 of 2196) observed prevalence of malignancy in O-RADS 2, 4% (34 of 857) in O-RADS 3, 27% (246 of 904) in O-RADS 4, and 78% (732 of 939) in O-RADS 5; the corresponding results for the IOTA 2-step strategy were 0.9% (18 of 1984), 4% (58 of 1304), 30% (206 of 690), and 82% (756 of 927). At the 10% risk threshold (O-RADS 4-5), the O-RADS lexicon had 92% sensitivity (95% CI, 87%-96%) and 80% specificity (95% CI, 74%-85%), and the IOTA 2-step strategy had 91% sensitivity (95% CI, 84%-95%) and 85% specificity (95% CI, 80%-88%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this external diagnostic validation study suggest that both the O-RADS lexicon and the IOTA 2-step strategy can be used to stratify patients into risk groups. However, the observed malignancy rate in O-RADS 2 was not clearly below 1%.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.5969","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T11:04:23Z","timestamp":1671102263000},"page":"225","source":"Crossref","is-referenced-by-count":54,"title":["External Validation of the Ovarian-Adnexal Reporting and Data System (\n O-RADS)<\/scp>\n Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into\n O-RADS<\/scp>\n Risk Groups"],"prefix":"10.1001","volume":"9","author":[{"given":"Stefan","family":"Timmerman","sequence":"first","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lil","family":"Valentin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Ceusters","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia C.","family":"Testa","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze della Salute della Donna, del Bambino e di Sanit\u00e0 Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCSS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Landolfo","sequence":"additional","affiliation":[{"name":"Queen Charlotte\u2019s and Chelsea Hospital, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Povilas","family":"Sladkevicius","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Van Holsbeke","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ziekenhuis Oost-Limburg, Genk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Domali","sequence":"additional","affiliation":[{"name":"First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, University of Milan\u2013Bicocca, San Gerardo Hospital, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, Karolinska Institutet and Department of Obstetrics and Gynecology, S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorella","family":"Franchi","sequence":"additional","affiliation":[{"name":"Preventive Gynecology Unit, Division of Gynecology, European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek J.","family":"Kudla","sequence":"additional","affiliation":[{"name":"Department of Perinatology and Oncological Gynecology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Chiappa","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Institute of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Alcazar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, School of Medicine, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco P. G.","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Biomedical and Clinical Sciences Institute L. Sacco, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Buonomo","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health\u2013IRCCS \u201cBurlo Garofolo,\u201d Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabetta","family":"Coccia","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Guerriero","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Deo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Whipps Cross Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligita","family":"Jokubkiene","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kaijser","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ikazia Hospital, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze della Salute della Donna, del Bambino e di Sanit\u00e0 Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCSS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Timmerman","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bourne","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Queen Charlotte\u2019s and Chelsea Hospital, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Van Calster","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Froyman","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi220077r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"coi220077r2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/IGC.0000000000000767","article-title":"European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery.","volume":"26","author":"Querleu","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"coi220077r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007945.pub2","author":"Woo","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"coi220077r4","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.ejso.2010.06.006","article-title":"Patterns of care in surgery for ovarian cancer in Europe.","volume":"36","author":"Verleye","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"coi220077r5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.","volume":"106","author":"Engelen","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"coi220077r6","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/AOG.0b013e3182922a17","article-title":"Adherence to treatment guidelines for ovarian cancer as a measure of quality care.","volume":"121","author":"Bristow","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"1","key":"coi220077r7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1148\/radiol.2019191150","article-title":"O-RADS US Risk Stratification and Management System: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee.","volume":"294","author":"Andreotti","year":"2020","journal-title":"Radiology"},{"key":"coi220077r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5920","author":"Van Calster","year":"2014","journal-title":"BMJ"},{"key":"coi220077r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2614","author":"Van Calster","year":"2020","journal-title":"BMJ"},{"key":"coi220077r10","doi-asserted-by":"publisher","journal-title":"Ultrasound Obstet Gynecol","DOI":"10.1002\/uog.v61.2"},{"issue":"1","key":"coi220077r11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1148\/radiol.211868","article-title":"External validation of O-RADS US risk stratification and management system.","volume":"304","author":"Hack","year":"2022","journal-title":"Radiology"},{"key":"coi220077r12","doi-asserted-by":"publisher","DOI":"10.1002\/jum.v41.6","article-title":"Comparison of O-RADS, GI-RADS, and ADNEX for diagnosis of adnexal masses: an external validation study conducted by junior sonologists.","author":"Lai","year":"2022","journal-title":"J Ultrasound Med"},{"key":"coi220077r13","doi-asserted-by":"publisher","DOI":"10.1002\/uog.v59.5","article-title":"Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in discriminating between benign and malignant adnexal lesions in North American population.","author":"Hiett","year":"2022","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"coi220077r14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2021.04.031","article-title":"Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): analysis on 1054 adnexal masses.","volume":"162","author":"Cao","year":"2021","journal-title":"Gynecol Oncol"},{"key":"coi220077r15","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-00947-9","author":"Xie","year":"2022","journal-title":"J Ovarian Res"},{"issue":"2","key":"coi220077r16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00330-020-07143-7","article-title":"Comparison of O-RADS, GI-RADS, and IOTA Simple Rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal masses.","volume":"31","author":"Basha","year":"2021","journal-title":"Eur Radiol"},{"key":"coi220077r17","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-08803-6","article-title":"Comparison of the O-RADS and ADNEX models regarding malignancy rate and validity in evaluating adnexal lesions.","author":"Chen","year":"2022","journal-title":"Eur Radiol"},{"key":"coi220077r18","doi-asserted-by":"publisher","DOI":"10.1177\/02841851221087376","article-title":"Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours.","author":"Wang","journal-title":"Acta Radiol"},{"issue":"1","key":"coi220077r19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1148\/radiol.211367","article-title":"Deep learning prediction of ovarian malignancy at US compared with O-RADS and expert assessment.","volume":"304","author":"Chen","year":"2022","journal-title":"Radiology"},{"key":"coi220077r20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17646","author":"Solis Cano","year":"2021","journal-title":"Cureus"},{"issue":"10","key":"coi220077r21","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1007\/s00261-021-03193-7","article-title":"Diagnostic accuracy and inter-observer reliability of the O-RADS scoring system among staff radiologists in a North American academic clinical setting.","volume":"46","author":"Pi","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"3","key":"coi220077r22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.14366\/usg.21237","article-title":"A comparison of the diagnostic performance of the O-RADS, RMI4, IOTA LR2, and IOTA SR systems by senior and junior doctors.","volume":"41","author":"Guo","year":"2022","journal-title":"Ultrasonography"},{"key":"coi220077r23","doi-asserted-by":"publisher","DOI":"10.21608\/aimj.2021.90943.1551","author":"Ahmed","year":"2021","journal-title":"Al-Azhar Int Med J"},{"key":"coi220077r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16370","author":"Jha","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"coi220077r25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S1470-2045(18)30837-4","article-title":"Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.","volume":"20","author":"Froyman","year":"2019","journal-title":"Lancet Oncol"},{"key":"coi220077r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5527","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"coi220077r27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-2006-933605","article-title":"Minimum training recommendations for the practice of medical ultrasound.","volume":"27","author":"Education and Practical Standards Committee, European Federation of Societies for Ultrasound in Medicine and Biology","year":"2006","journal-title":"Ultraschall Med"},{"issue":"5","key":"coi220077r28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1046\/j.1469-0705.2000.00287.x","article-title":"Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group.","volume":"16","author":"Timmerman","year":"2000","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"coi220077r29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bpobgyn.2003.10.002","article-title":"Use of morphology to characterize and manage common adnexal masses.","volume":"18","author":"Valentin","year":"2004","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"34","key":"coi220077r30","doi-asserted-by":"publisher","first-page":"8794","DOI":"10.1200\/JCO.2005.01.7632","article-title":"Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.","volume":"23","author":"Timmerman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi220077r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum.","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"coi220077r32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/uog.11177","article-title":"Clinically oriented three-step strategy for assessment of adnexal pathology.","volume":"40","author":"Ameye","year":"2012","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"coi220077r33","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/bjc.2014.333","article-title":"Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study.","volume":"111","author":"Testa","year":"2014","journal-title":"Br J Cancer"},{"issue":"10","key":"coi220077r34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"coi220077r35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jclinepi.2012.03.006","article-title":"Bivariate meta-analysis of predictive values of diagnostic tests can be an alternative to bivariate meta-analysis of sensitivity and specificity.","volume":"65","author":"Leeflang","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"coi220077r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4770","author":"de Groot","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"coi220077r39","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration.","volume":"170","author":"Moons","year":"2019","journal-title":"Ann Intern Med"},{"key":"coi220077r36","unstructured":"IOTA-ADNEX model. Accessed September 9, 2022. https:\/\/www.iotagroup.org\/sites\/default\/files\/adnexmodel\/IOTA%20-%20ADNEX%20model.html"},{"key":"coi220077r37","unstructured":"ACR guidance app. Accessed September 9, 2022. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/O-RADS\/ACR-Guidance-App.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2799493\/jamaoncology_timmerman_2022_oi_220077_1675884569.54075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T11:02:30Z","timestamp":1676545350000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2799493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.5969","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}